0001127602-21-015352.txt : 20210504 0001127602-21-015352.hdr.sgml : 20210504 20210504191550 ACCESSION NUMBER: 0001127602-21-015352 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210430 FILED AS OF DATE: 20210504 DATE AS OF CHANGE: 20210504 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Graham Jonathan P CENTRAL INDEX KEY: 0001365306 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 21890506 MAIL ADDRESS: STREET 1: 2099 PENNSYLVANIA AVENUE, NW STREET 2: 12TH FLOOR CITY: WASHINGTON STATE: DC ZIP: 20006 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2021-04-30 0000318154 AMGEN INC AMGN 0001365306 Graham Jonathan P ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 1 EVP, Gen. Counsel & Secy. Common Stock 2021-04-30 4 A 0 3797 0 A 47762 D Common Stock 2021-05-01 4 F 0 581 239.64 D 47181 D Common Stock 2021-05-03 4 F 0 548 239.64 D 46633 D Nqso (Right to Buy) 239.64 2021-04-30 4 A 0 32971 0 A 2023-04-30 2031-04-30 Common Stock 32971 32971 D The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. These shares include the following RSUs granted under the Company's equity plans: 1,073 RSUs which will vest on 4/27/2022; 2,116 RSUs which vest in installments of 1,042 on 5/3/2022 and 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; and 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 712 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively. /s/ Jonathan P. Graham 2021-05-04